Does rivaroxaban reduce venous thromboembolism in acutely ill medical patients compared to enoxaparin?
Extended-duration rivaroxaban reduces VTE risk in acutely ill medical patients but is associated with an increased risk of bleeding.
In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).
Cohen et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: